Background {#Sec1}
==========

Psychotic disorders, including schizophrenia, are potentially devastating lifelong illnesses that are disabling and costly to patients, families, communities and healthcare systems. Symptoms typically emerge during late adolescence, and the estimated lifetime prevalence and incidence is approximately 0.3--0.7 % \[[@CR1]\].

Treatment advances in these heterogeneous disorders have been limited by insufficient mechanistic understanding of the underlying pathophysiology. Thus far, pharmacological treatments have been based on the premise of disrupted dopaminergic neurotransmission, but the exact nature of dopamine (DA) dysregulation remains complex \[[@CR2]\].

One of the more recent theories of psychosis suggests that an aberrant brain reward system could explain some of the disorder's clinical symptoms \[[@CR3]\]. Anticipation of reward represents motivational behaviour or drive ("wanting"), which is associated with activation of the typical cortical-basal ganglia circuit \[[@CR4]\] and particularly modulated by dopamine in the ventral striatum. Consequently, dopamine depletion results in lack of motivational drive, apathy \[[@CR5]\] and reduced brain activity in striatum and cingulate gyrus during anticipation of reward \[[@CR6]\], whereas amphetamine-induced dopamine release in striatal brain regions has been associated with pleasant emotions of anticipation \[[@CR5], [@CR7]\]. Over recent years, several functional magnetic resonance imaging (fMRI) studies have demonstrated alterations in the brain reward network in patients with, and at clinical high risk for, psychosis, primarily in the striatal motivational system \[[@CR8]--[@CR13]\].

One of the most important proteins that regulate extracellular brain dopamine concentrations is catechol-O-methyl-transferase (COMT), an enzyme catabolising released dopamine in cortical, particularly prefrontal, areas \[[@CR14]\]. A functional single nucleotide polymorphism, Val158Met of the COMT gene (Val/Met), has been suggested to lead to a 40 % reduction in enzyme activity and has been shown to affect cortical DA metabolism levels, with Val carriers displaying lower extracellular DA levels than Met-carriers \[[@CR15]\]. This polymorphism contributes to measurable individual differences in human cognitive function \[[@CR16]--[@CR18]\]. Moreover, fMRI studies in healthy participants have shown that frontal and striatal activation during anticipation of reward is dependent on COMT genotype with Met homozygotes showing larger brain response than Val homozygotes \[[@CR19], [@CR20]\].

Interestingly, the gene for COMT is located at chromosome 22q11.2, a chromosomal region that has received an interest from psychiatric geneticists for over 20 years. A deletion at 22q11.2 is the first and only copy number variant unequivocally implicated in psychotic disorders: people with 22q11 deletion syndrome (22q11DS) carry a 25- to 30-fold increased risk of psychosis \[[@CR21]--[@CR23]\]. This shared genetic variant that greatly increases risk for psychosis makes individuals with 22q11DS a relatively homogeneous population to study psychotic vulnerability. Thus, 22q11DS can provide unique insights into risk and protective factors for psychotic vulnerability that not only benefit patients with 22q11DS but also could help patients with psychosis that do not have this particular deletion.

COMT haplo-insufficiency in 22q11DS has been suggested as one explanation for the increased susceptibility for psychosis in 22q11DS. Indeed, it has been demonstrated that people with 22q11DS have reduced COMT gene expression \[[@CR24], [@CR25]\], enzyme activity \[[@CR25]\] and alterations in dopaminergic neurotransmission \[[@CR26], [@CR27]\]. Because of a paucity of dopamine transporter expression in the frontal lobe, dopamine metabolism is largely dependent on COMT in frontal brain regions. Therefore, effects of reduced COMT gene dosage are expected to be most pronounced in frontal brain regions in subjects with 22q11DS \[[@CR25], [@CR28]\]. In addition, the Val/Met polymorphism may have a larger effect in 22q11DS because only one copy of the allele is present, and COMT Met hemi-zygotes may have extremely low COMT activity \[[@CR15], [@CR17], [@CR25], [@CR29], [@CR30]\]. While COMT haplo-insufficiency has been proposed as one explanation for the increased risk of psychosis in 22q11DS, it should be noted that, overall, the association between COMT genotype and psychosis remains inconclusive \[[@CR31]--[@CR33]\].

The consequences of COMT haplo-insufficiency in humans with 22q11DS at a neuronal level, and how this relates to psychotic symptomatology is still unclear. More specifically, the effect of the 22q11.2 deletion and COMT haplo-insufficiency on reward processing is still unknown. We therefore explored for the first time reward processing in adults with 22q11DS using a reward anticipation fMRI paradigm. We hypothesized that adults with 22q11DS, because of their increased susceptibility for psychosis, would not recruit brain regions that would normally be recruited during motivational behaviour. In addition, we hypothesized that, in 22q11DS, brain activation during reward processing would be modulated by COMT Val/Met genotype.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

Adult individuals with 22q11DS (*n* = 16) were recruited through the Dutch 22q11DS family association and several Dutch Clinical Genetics Centres. Healthy volunteers (*n* = 12) were recruited by local advertisement as described previously and are partially overlapping with the healthy volunteers of our previous studies \[[@CR6], [@CR34]\]. The study was conducted at the Department of Psychiatry, Academic Medical Centre Amsterdam, The Netherlands, and was approved by the local Medical Ethics Committee. All participants were capable of giving written informed consent and did so, after receiving full information on the study. All individuals with 22q11DS were interviewed by a physician using a semi-structured psychiatric interview. Patients with 22q11DS with psychosis were all on anti-psychotic medication and two 22q11DS patients without psychosis were using selective serotonin reuptake inhibitors (SSRIs) at the time of testing (Table [1](#Tab1){ref-type="table"}). None of the healthy participants had a history of psychiatric disorders, medical conditions affecting brain function and substance or alcohol abuse, and they were not using any medication at the time of testing.Table 1Characteristics of participants22q11DS (*n* = 16)Controls (*n* = 12)*p*Age (SD)28.2 (6)29 (9.6)0.79Gender (M/F)8/88/40.46IQ (SD)77 (10)110 (10)\<0.001Psychosis (Y/N)5/11COMT genotype (Met/Val)6/10PANSS total45.5PANSS positive8.4PANSS negative13.9Medication (*n*)Quetiapine (3)Risperidone (1)Lithiumcarbonate (1)Paroxetine (1)Methylphenidate (1)Venlafaxine (1)Clozapine (1)Lamotrigine (1)

The Positive and Negative Symptom Scale (PANSS) \[[@CR35]\] was used to assess positive, negative and general psychopathology in the 22q11DS group. In addition, for assessment of intelligence quotient (IQ), we used the shortened Dutch version of the Wechsler Adult Intelligence Scale (WAIS-III-NL) consisting of five subtests: vocabulary, comprehension, similarities (verbal IQ), block design and object assembly (performance IQ) \[[@CR36], [@CR37]\]. For demographics and clinical variables, see Table [1](#Tab1){ref-type="table"}.

Genotyping {#Sec4}
----------

Blood samples were collected from all subjects with 22q11DS participants. DNA was isolated from blood using standard procedures (Gentra Technology, Qiagen). Genotyping using 5′-nuclease Taqman assays for allelic discrimination (Life Technologies, Foster City, California, USA) was carried out with a LC-480 384-well Lightcycler (Roche Diagnostics, Mannheim, Germany) \[[@CR38]\]. COMT Val^158^Met (rs4680) genotype was determined with Taqman assay C.25746809 A/G (Life Technologies). The Lightcycler LC-480 Software release 1.5.0 was used to analyse end point fluorescence.

FMRI task: monetary incentive delay {#Sec5}
-----------------------------------

We used event-related fMRI to assess blood-oxygen-level dependent (BOLD) brain activation during the monetary incentive delay (MID) task (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR39]\]. In short, the MID task was used to evoke anticipation of potential monetary reward, loss or no consequential outcome. It consists of two sessions of 72 trials of 6 s, yielding a total of 144 trials and total duration of 14 min. During each trial, subjects were shown one of seven cues. Cues signaling reward were denoted by circles (*n* = 54), loss by squares (*n* = 54) and no monetary outcome by triangles (*n* = 36). The amount of money that subjects were able to win was indicated by one horizontal line (0.20 Euro), two lines (1.00 Euro) and three lines (5.00 Euros). Similarly, loss cues signalled the possibility of losing the same amounts of money. Subjects had to respond to the white target square that appeared for a variable length of time. To succeed in a trial, volunteers had to press the button during the time that the white square target was visible (target, 160--260 ms). Unlike the MID described by Knutson et al. \[[@CR35]\], we did not pay the amount of money earned during the task; reward and loss was based on point scoring \[[@CR6], [@CR34]\].Fig. 1Monetary incentive delay task, structure for a representative trial

MRI data acquisition {#Sec6}
--------------------

FMRI data were collected using a 3T MRI Philips system equipped with a sense head coil as previously explained \[[@CR6], [@CR34]\]. The task stimuli were generated using e-prime software (SCOPE V2.5.4/Pentium). For the MID task 360 event related, transversal multi-slice T2\*-weighted gradient-echo planar images (EPI) were acquired with echo time (TE) 30 ms, repetition time (TR) 2000 ms, 96 × 96 matrix, 35 slices, 3 × 3 mm in-plane resolution, slice thickness 3 mm with a 1-mm interslice gap, covering the entire brain. For anatomical localization, transversal high-resolution structural T1-weighted volumetric images were acquired in the same session, with full head coverage, using 150 contiguous slices (1-mm thick, with 0.89 × 0.89 mm in-plane resolution), a 256 × 256 × 124 matrix and a TR/TE of 24/5 ms (flip angle 45°, FOV 24 cm).

FMRI data analyses {#Sec7}
------------------

All functional and structural brain images were pre-processed with the researcher blind for group status, as previously explained \[[@CR6]\].

### FMRI data pre-processing {#Sec8}

Slice time correction was used to adjust for time differences due to multi-slice image acquisition. The functional images were realigned to the first volume of the time series to correct for head movements. After co-registering functional images to the anatomical image, they were spatially normalized to the standard space of the Montreal Neurological Institute brain (MNI-brain). All functional images were sub-sampled to a voxel size of 2 × 2 × 2 mm. Normalized images were smoothed with a Gaussian kernel of 8-mm full width at half maximum.

### FMRI data statistical analysis {#Sec9}

The analyses focused on changes in blood-oxygen-level dependent (BOLD) contrast that occurred during anticipatory delay periods and were conducted using SPM8 (Wellcome Department of Cognitive Neurology, London, UK). The pre-processed fMRI data were analysed in the context of the general linear model (GLM) approach \[[@CR40]\] using a two-level procedure.

At the first level, seven conditions (Reward~High~, Reward~Medium~, Reward~Low~, Neutral, Loss~High~, Loss~Medium~, Los~low~) were modelled by a boxcar function convolved with a hemodynamic response function. The movement parameters were included as confounds in the design matrix. Changes in the BOLD response were assessed using the estimated GLM parameters for the anticipation of potential monetary gain vs. anticipation of no monetary outcome (reward vs. neutral) and the anticipation of potential monetary loss vs. anticipation of no monetary outcome (loss vs. neutral). In the second level analysis, individual contrast images of the first level analysis were included in a two-sample *t* test to detect relevant brain activation in patients with 22q11DS and in healthy controls. Subsequently, within the 22q11DS group, effects of COMT genotype and PANSS scores on brain activation were tested. For the whole brain analysis, comparisons were corrected for multiple comparisons using family wise error correction (FWE~cor~) *p* \< 0.05 at the cluster level (extent threshold of 10 voxels).

Results {#Sec10}
=======

Demographic characteristics {#Sec11}
---------------------------

Patients with 22q11DS did not differ in age compared to healthy controls (22q11DS 28.2 years ± 6.0 vs controls 29 years ± 9.6, *p* = 0.79). Also, gender distribution was not significantly different between the two groups (22q11DS M/F ratio 8/8; controls M/F ratio 8/4; *p* = 0.46, Fisher's exact test). 22q11DS patients and healthy controls differed in total IQ scores (HC 110 (10) and 22qDS 77 (10), *p* \< 0.001). Within the 22q11DS group, 5 had a psychotic disorder, 6 were Val hemizygote and 10 were Met hemizygote (Table [1](#Tab1){ref-type="table"}).

Task performance {#Sec12}
----------------

Repeated measures ANOVA showed no significant main effect of group (*p* = 0.25) on reaction time performance. Reaction times in healthy controls in reward (243.4 ms ± 29.3) and loss (250.7 ms ± 38.4) conditions did not differ from those in patients with 22q11DS (reward 231.8 ms ± 29.2; loss 230.1 ms ± 29.3). There was no main effect of incentive value (*p* = 0.26) on reaction time performance and no significant interaction effect (incentive value\*group, *p* = 0.09).

FMRI results {#Sec13}
------------

### Patients with 22q11DS {#Sec14}

During *anticipation of reward*, patients with 22q11DS significantly activated a large cluster (23,094 voxels) encompassing the bilateral middle frontal lobe and bilateral middle and superior temporal lobe (*p*~FWE~ \< 0.001 corrected for multiple comparisons at cluster level, Table [2](#Tab2){ref-type="table"}). During *anticipation of loss,* patients with 22q11DS showed activation in a cluster (19786 voxels) including the left middle frontal gyrus and the anterior cingulate cortex (*p*~FWE~ \< 0.001, Table [2](#Tab2){ref-type="table"}).Table 2Peak level coordinates in the significant^\*^ cluster during anticipation of rewardGroupBrain structureBAMNI coordinates*T* scorexyz22q11DSLHypothalamusNA−10−6−84.83RInferior frontal gyrus472618−125.08LMedial frontal gyrus6−10−30745.35LMiddle frontal gyrus8−2420484.53RMiddle frontal gyrus10345004.53LMiddle temporal gyrus21−52−4644.37RMiddle temporal gyrus2154−24−124.64RPutamenNA28−10124.64LSuperior temporal gyrus39−34−58284.52RSuperior temporal gyrus4156−2044.63ControlsLCingulate gyrus24−4−10407.79RCingulate gyrus244−12407.26RCingulate gyrus234−16346.96RCingulate gyrus234−32285.52RCingulate gyrus242−18449.02RCingulate gyrus234−12305.64RMiddle occipital gyrus1832−88−87.39LPosterior cingulate23−2−30249.25RPrecentral gyrus420−28726.22LPrecuneus31−8−62225.73RPrecuneus3120−78266.58RSuperior frontal gyrus6616685.69LTransverse temporal gyrus41−42−30126.0822q11DS \> controlsNo significant resultsControls \> 22q11DSLCingulate gyrus24−4−12383.10LCingulate gyrus24−8−20403.24RCingulate gyrus244−12404.63RCingulate gyrus234−30283.28RCingulate gyrus242−20405.03RCingulate gyrus3112−32423.24RMedial frontal gyrus610−12743.66LParacentral lobule5−8−44503.12RParacentral lobule46−42723.10RPostcentral gyrus412−38604.60LPrecuneus31−2−70243.31\* *p* \< 0.001 FWE- corrected at cluster level*L* left, *R* right, *BA* Brodmann area

Within the 22q11DS group without psychosis (*n* = 11), the same regions were found as in the total 22q11DS group during anticipation of reward (same peak clusters, less significant *p*~FWE~ \< 0.001 corrected) and during anticipation of loss (same peak clusters, not significant (*p*~FWE~ = 0.140)).

Within the 22q11DS group, there was no relation between PANSS scores and reward or loss related brain activity.

### Patients with 22q11DS vs. healthy controls {#Sec15}

During *anticipation of reward*, patients with 22q11DS, compared to controls, showed reduced activation (*p*~FWE~ \< 0.001) in a cluster (9271 voxels) covering the bilateral cingulate gyrus extending to premotor, primary motor and somatosensory areas (Table [3](#Tab3){ref-type="table"}, Fig. [2a](#Fig2){ref-type="fig"}). During *anticipation of loss*, patients with 22q11DS showed reduced activation (*p*~FWE~ \< 0.05) in a cluster (3147 voxels) encompassing the left posterior cingulate cortex and extending bilaterally to the cuneus and precuneus (Table [3](#Tab3){ref-type="table"}, Fig. [2b](#Fig2){ref-type="fig"}).Table 3Peak level coordinates in the significant^\*^ cluster during anticipation of LossGroupBrain structureBAMNI coordinates*T* score*xyz*22q11DSLCingulate gyrus24−6−6345.29LCingulate gyrus24−106384.14LHippocampusNA−28−22−83.96LHypothalamusNA−8−6−105.44RMedial frontal gyrus6100664.14LMiddle frontal gyrus6−26−4644.34LMiddle frontal gyrus11−3244−84.07RMiddle frontal gyrus63010603.93RMiddle frontal gyrus103438226.04ControlsRCingulate gyrus242−12366.43RCingulate gyrus242−16444.96RCingulate gyrus2410−12404.12LInsula13−328184.17RMedial frontal gyrus610−14544.99RMedial frontal gyrus610−16584.59LMiddle frontal gyrus11−3036−125.62RMiddle frontal gyrus626−18664.75RMiddle frontal gyrus92832324.59RPrecentral gyrus420−26685.29RPrecentral gyrus624−16744.08RSuperior temporal gyrus4148−2884.0722q11DS \> controlsNo significant resultsControls \> 22q11DSLCuneus18−4−80242.78LCuneus18−4−90122.74LCuneus18−10−88122.80LCuneus18−8−84203.06RCuneus1818−84263.62RCuneus1810−82262.84RCuneus1816−86163.01RCuneus722−84322.95RCuneus722−80283.00LMiddle occipital gyrus19−28−82142.89LPosterior cingulate23−4−54222.86LPrecuneus31−2−72263.11LPrecuneus31−6−68243.20LPrecuneus310−78242.81LPrecuneus31−24−78142.70RPrecuneus714−70522.71\**p* \< 0.001 FWE-corrected at cluster level*L* left, *R* right, *BA* Brodmann areaFig. 2SPM *t* value for healthy controls vs. 22q11DS patients showing significant reduced BOLD activation in 22q11DS patients in the cingulate cortex, primary motor and somatosensory areas during anticipation of reward (**a**) and in posterior cingulate cortex and cuneus during anticipation of loss (**b**)

### 22q11DS Val hemizygotes vs. 22q11DS Met hemizygotes {#Sec16}

Within the 22q11DS group, anticipation of reward resulted in more activation of the right posterior cingulate and bilateral parietal regions in Val hemizygotes compared to Met hemizygotes (cluster size 3008 voxels, *p*~FWE~ \< 0.05, Table [4](#Tab4){ref-type="table"}, Fig. [3a](#Fig3){ref-type="fig"}). Anticipation of loss resulted in significantly more activation in the bilateral insula, striatum and left anterior cingulate in Met hemizygotes compared to Val hemizygotes (Cluster size: 4481 voxels, Table [4](#Tab4){ref-type="table"}, Fig. [3b](#Fig3){ref-type="fig"}).Table 4Peak level coordinates in the significant^\*^ cluster during anticipation of reward and loss in 22q11DS COMT Val and Met hemizygotesReward-neutralGroupBrain structureBAMNI coordinates*T* score*xyz* Val \> MetLCingulate gyrus31−6−48342.77LCingulate gyrus31−4−40442.57RCingulate gyrus234−28282.86RMiddle frontal gyrus616−8622.63RParacentral lobule46−38623.48RParacentral lobule58−42582.99LPostcentral gyrus3−20−32562.93RPostcentral gyrus310−36663.67RPostcentral gyrus324−34583.09RPosterior cingulate306−46202.59RPrecentral gyrus432−32563.24RPrecentral gyrus434−30683.05RPrecentral gyrus426−30643.01RPrecentral gyrus622−24682.73LPrecuneus31−10−48362.69RPrecuneus712−66403.00 Met \> ValNo significant resultsLoss-neutralGroupBrain structureBAMNI coordinates*T* score*xyz* Val \> MetNo significant results− Met \> ValLAnterior cingulate24−230202.91LCaudate bodyNA−12−2203.42RCaudate bodyNA10−2202.84LCingulate gyrus23−6−34283.58LCingulate gyrus31−16−40282.88LInsula13−34−6162.86LPosterior cingulate23−2−40223.29LPutamenNA−24−12162.89LSuperior temporal gyrus22−64−4282.79LThalamusNA−18−8142.73\**p* \< 0.05 FWE-corrected at cluster level*L* left, *R* right, *BA* Brodmann areaFig. 3SPM *t* value for 22q11DS Val vs. Met hemizygotes showing significant increased BOLD activation in Val hemizygotes in the cingulate cortex and parietal regions during anticipation of reward (**a**) and reduced activation in anterior cingulate cortex, striatum and insula during anticipation of loss (**b**)

Discussion {#Sec17}
==========

To our knowledge, this is the first study to investigate the neural substrates of reward processing in people with 22q11DS, a population at high risk of developing a psychotic illness. Our main fMRI findings suggest that reward anticipation in 22q11DS engages a fronto-temporal network. Compared to healthy controls, people with 22q11DS primarily displayed reduced activity in medial frontal regions during reward anticipation. During anticipation of loss, a reduction in bilateral (pre)cuneus and left posterior cingulate activity was observed. Further analyses also revealed an effect of COMT genotype on the 22q11DS reward anticipation network.

The dysfunctional 22q11DS reward processing network {#Sec18}
---------------------------------------------------

The 22q11DS reward anticipation network seems different from healthy controls in several ways. During anticipation of reward, reduced activity in the cingulate gyrus and medial frontal brain regions was observed. These are all key structures of the reward circuitry in healthy controls \[[@CR4], [@CR6], [@CR39], [@CR41]--[@CR43]\].

Decreased cingulate gyrus activity during reward anticipation could be related to impairments in predicting reward outcome, since this region is related to prediction error in reinforcement learning \[[@CR44]--[@CR46]\]. Reduced activation in medial frontal brain regions in 22q11DS during reward and posterior cingulate and (pre)cuneus brain regions during loss may be a reflection or consequence of the anatomical abnormalities typically seen in people with 22q11DS. These alterations include grey matter reductions in frontal and temporal regions and widespread white matter reductions primarily in the posterior lobe \[[@CR47]--[@CR51]\].

In contrast to other studies \[[@CR11], [@CR52]\], we were not able to find significant activity in the ventral striatum during reward processing, a core region of the reward network \[[@CR4], [@CR11], [@CR39], [@CR53], [@CR54]\]. This could be due to the small sample size and the small area that includes the ventral striatum. Moreover, the mixed gender group in our study could have affected the results, since anticipation of monetary reward differentially activates mesolimbic brain regions in women compared to men \[[@CR55]\].

Interestingly, similarities in the reward anticipation network exist between 22q11DS and the schizophrenia spectrum. In line with our findings in 22q11DS, previous studies in unmedicated schizophrenia patients showed reduced activity in the cingulate gyrus \[[@CR49], [@CR56]\] and a recent study in siblings of schizophrenia patients, at increased genetic risk for schizophrenia, found fronto-striatal dysfunctioning during reward anticipation \[[@CR57]\]. Behavioural studies furthermore found evidence for impaired functioning on reward tasks that depend on cortical regions in people with schizophrenia, which is in line with our results and suggested to be associated with negative symptoms \[[@CR58], [@CR59]\]. Interestingly, the clinical pattern in 22q11DS is also characterized by predominant negative symptoms \[[@CR60], [@CR61]\].

The similarities in the reward network between 22q11DS and schizophrenia spectrum may indicate that 22q11DS is associated with similar behavioural impairments typically seen in schizophrenia such as anhedonia, decreased motivation and a lack of reward sensitivity \[[@CR11], [@CR62]--[@CR64]\]. Future studies should further investigate the presence of these symptoms in relation to the reward processing network in 22q11DS.

Lastly, it is interesting to speculate on the implications of abnormal reward-related activity for the behavioural phenotype in 22q11DS. This may suggest a decreased hedonic component of reward anticipation and, as such, could have implications for (risk of) addiction and substance abuse in 22q11DS \[[@CR65]\]. Interestingly, in contrast to schizophrenia patients \[[@CR66]\] and the general population, only a small percentage of 22q11DS patients suffer from addiction and display substance abuse \[[@CR60], [@CR65], [@CR67]\], possibly suggesting aberrant reward sensitivity. The link between abnormal reward-related brain activity and reward seeking behaviour in 22q11DS requires further investigation.

COMT genotype effects on 22q11DS reward processing {#Sec19}
--------------------------------------------------

In line with previous studies investigating reward anticipation with fMRI in healthy controls \[[@CR19], [@CR68]\], we found an effect of COMT genotype on reward processing. However, the present results should be considered preliminary due to the small sample size of the COMT genotype subgroups. We observed that the high-activity Val allele compared to Met allele carriers was associated with increased activity in posterior cingulate and parietal regions during anticipation of reward. Whereas the low-activity Met allele, compared to Val allele, was associated with increased activity in the anterior cingulate cortex and striatum during anticipation of loss. These results are in line with previous fMRI research in 22q11DS showing less efficient cingulate activity in Met-carriers, during a response inhibition task \[[@CR69]\]. This is furthermore supported by structural findings in 22q11DS adults showing that the COMT Met allele was associated with decreased frontal lobe volume \[[@CR70]\], which is consistently found to have abnormal functioning and structure in 22q11DS \[[@CR47], [@CR49]\]. While preliminary, these results are noteworthy because they provide clues on the underlying reward-related alterations in neurochemical signaling in 22q11DS, which could lead to more insight in possible treatment targets \[[@CR71]\].

Variation in COMT genotype has been associated with altered cortico-striatal dopaminergic activity \[[@CR72], [@CR73]\]. 22q11DS COMT hemizygosity has been associated with decreased cortical COMT expression and enzyme activity, possibly greatly increasing extracellular DA in 22q11DS Met-carriers and moderately increasing extracellular DA in 22q11DS Val carriers \[[@CR24], [@CR25]\].

Met-hemizygosity in 22q11DS is associated with worse prefrontal cognitive functioning, possibly related to increased levels of tonic DA and decreased phasic DA release \[[@CR73], [@CR74]\]. Alterations in DA function have previously also been implicated to play a role in reward-related dysfunction and the development of psychotic symptoms in schizophrenia \[[@CR3], [@CR7], [@CR75]\]. Moreover, lower striatal mean D2/3R binding has been found in Met hemizygotes, possibly reflecting higher synaptic DA levels \[[@CR76]\]. All in all, these findings may suggest that changes in dopamine function might explain the effect of COMT genotype on reward-related brain activity in frontal and striatal brain regions in 22q11DS. This explanation, however, remains speculative since the mechanism underlying COMT genotype effects on extracellular DA levels is thought to be far more complex because of the different isoforms and the suggested intracellular location of COMT \[[@CR14], [@CR77]--[@CR79]\] and our methods could not provide information on extracellular DA levels.

Lastly, the observation that brain activity associated with anticipation of reward and loss was differentially modulated by COMT genotype in 22q11DS may suggest that COMT genotype impacts preferred reward engagement strategies such as reward and loss seeking or aversion behaviour. This idea is supported by previous work hypothesizing that the Met genotype is associated with higher loss aversion \[[@CR68]\] and lower extraversion \[[@CR80]\].

Limitations and future directions {#Sec20}
---------------------------------

A limitation of the study is the relatively small sample size of the total and COMT specific sample, the presence of psychotic disorder in a part of the 22q11DS group and the use of medication in some subjects, which could have affected brain function \[[@CR81]\]. We reanalysed a subset of the 22q11DS group excluding the 22q11DS subjects with psychosis and replicated the majority of our prior fMRI results, finding the same peak clusters in botch conditions. However, in the anticipation of loss condition, the findings did not survive the level of significance, which could be the result of the smaller sample size. The present results should therefore be considered preliminary and replication is needed. In light of the rarity of the disorder and the challenge of recruitment, the sample size of the group however could be considered acceptable.

Future research could address some other limitations of this study. In line with previous studies that used a point scoring system \[[@CR34]\], our participants did not receive the actual money that they gained. Lack of a powerful reinforcer such as money might have influenced the participants' motivation to perform to the best of their abilities, possibly affecting activation patterns in brain reward regions.

Furthermore, given that the BOLD signal is a hemodynamic measure, the neurochemical mechanism behind alterations in the 22q11DS reward network is unclear. The observed between-group and COMT effects could reflect changes in catecholaminergic activity or downstream consequences of these changes on other neurotransmitter systems. Positron emission tomography (PET) studies in this disorder could be an important next step in investigating the degree of dopaminergic abnormalities during reward processing in 22q11DS.

Conclusions {#Sec21}
===========

This study is the first to investigate reward processing in 22q11DS. Our preliminary results suggest that people with 22q11DS engage a fronto-temporal neural network during reward processing and that, compared to controls, brain activation within the 22q11DS group is reduced in medial and frontal brain regions.

Similarities with the reward neural network within the schizophrenia spectrum were observed, which is in line with the clinical overlap between the behavioural impairments typically seen in 22q11DS and schizophrenia.

Our findings may be explained by the anatomical abnormalities typically seen in 22q11DS or by the COMT haplo-insufficiency in 22q11DS, which is hypothesized to result in primarily abnormal frontal DA levels and increased extracellular DA release in low-activity Met hemizygotes. In line with this notion, an effect of 22q11DS COMT genotype on reward processing was additionally observed, which may provide further clues on the underlying reward-related alterations in neurochemical signaling in 22q11DS and its possible relevance for psychotic disorder.
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